A phase II randomized study of cetuximab and bevacizumab alone or in combination with gemcitabine as first-line therapy for metastatic pancreatic adenocarcinoma

Author： Ko Andrew  

Publisher： Springer Publishing Company

ISSN： 0167-6997

Source： Investigational New Drugs, Vol.30, Iss.4, 2012-08, pp. : 1597-1606

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Phase II study of oral S-1 with irinotecan and bevacizumab (SIRB) as first-line therapy for patients with metastatic colorectal cancer

By Yamada Yasuhide  

Investigational New Drugs, Vol. 30, Iss. 4, 2012-08 ,pp. : 1690-1696

Springer Publishing Company

Access to resources Recommend Favorite

Multicenter, randomized phase II trial of bevacizumab plus folinic acid, fluorouracil, gemcitabine (FFG) versus bevacizumab plus folinic acid, fluorouracil, oxaliplatin (FOLFOX4) as first-line therapy for patients with advanced colorectal cancer

By Madajewicz Stefan  

Investigational New Drugs, Vol. 30, Iss. 2, 2012-04 ,pp. : 772-778

Springer Publishing Company

Access to resources Recommend Favorite

Bevacizumab: A Review of its Use in Combination with Paclitaxel or Capecitabine as First-Line Therapy for HER2-Negative Metastatic Breast Cancer

By Croom Katherine F.   Dhillon Sohita  

Drugs, Vol. 71, Iss. 16, 2011-11 ,pp. : 2213-2229

Adis International

Access to resources Recommend Favorite

Gemcitabine plus enzastaurin or single-agent gemcitabine in locally advanced or metastatic pancreatic cancer: Results of a Phase II, randomized, noncomparative study

By Richards Donald   Kuefler Paul   Becerra Carlos   Wilfong Lalan   Gersh Robert   Boehm Kristi   Zhan Feng   Asmar Lina   Myrand Scott   Hozak Rebecca   Zhao Luping   Gill John   Mullaney Brian   Obasaju Coleman   Nicol Steven  

Investigational New Drugs, Vol. 29, Iss. 1, 2011-02 ,pp. : 144-153

Springer Publishing Company

Access to resources Recommend Favorite

Gemcitabine and vinorelbine (GV) versus cisplatin, gemcitabine and vinorelbine (CGV) as first-line treatment in advanced non small cell lung cancer: Results of a prospective randomized phase II study

By Esteban Emilio   Fra Joaquin   Fernández Yolanda   Corral Norberto   Vieitez José   Palacio Isabel   Sande José   Fernández José   Muñiz Isabel   Villanueva Noemi   Estrada Enrique   Mareque Beatriz   Uña Esther   Buesa José   Lacave Angel  

Investigational New Drugs, Vol. 24, Iss. 3, 2006-05 ,pp. : 241-248

Springer Publishing Company

Access to resources Recommend Favorite